Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cybin ( (TSE:CYBN) ) is now available.
Cybin Inc. announced its upcoming annual general meeting of shareholders, scheduled for August 18, 2025, to be held virtually. Key agenda items include the presentation of audited financial statements for the year ending March 31, 2025, the appointment of Zeifmans LLP as the auditor for the upcoming year, and the election of directors. This meeting is crucial for stakeholders as it will address corporate governance and financial oversight, impacting the company’s strategic direction and operational transparency.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. operates in the biotechnology industry, focusing on the development of psychedelic-based therapies. The company is primarily engaged in creating innovative treatments for mental health disorders, leveraging psychedelic compounds to address unmet medical needs.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
For a thorough assessment of CYBN stock, go to TipRanks’ Stock Analysis page.